Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
The method of administration of [D-Ala5,D-Trp8] somatostatin is of central importance in determining the degree and duration of suppression of insulin and glucagon release. The analog decreased insulin levels in rats when injected by s.c. or i.v. routes, with a nadir 15 minutes following injection. After i.v. injection, insulin levels rapidly returned to basal values while s.c. injection produced significant suppression for 60 minutes. Neither type of injection altered glucagon levels. Intravenous infusion resulted in inhibition of both insulin and glucagon release, with rebound hyperglucagonemia, but not hyperinsulinemia in the post-infusion period. Plasma glucose levels reflected these hormonal changes. Thus, dramatic alterations in the specificity of this somatostatin analog may be achieved by employing different methods of administration.
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D005934:Glucagon / Q000097:blood*; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood*; D007700:Kinetics; D008297:Male; D051381:Rats; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
D001786:Blood Glucose; D007328:Insulin; C018814:somatostatin, Ala(5)-Trp(8)-; D013004:Somatostatin; D005934:Glucagon